Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05574101 · ClinicalTrials.gov registry record · Phase 2
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
A Phase 2 study of Squamous Cell Carcinoma and Skin Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 13
- Study locations
NCT05574101 is a Phase 2 study of Squamous Cell Carcinoma and Skin Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 34 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (67% lower). The trial reports 13 study locations across 8 states.
The verdict
NCT05574101, a Phase 2 study of Squamous Cell Carcinoma and Skin Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
Conditions Studied
Interventions
- DRUG Cemiplimab
- RADIATION Radiotherapy
Study Locations (13)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Cancer Center at Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All protocol activities) - Montvale
Colorado
- University of Colorado (Data Collection Only) - Aurora
Florida
- Moffitt Cancer Center (Data Collection Only) - Tampa
Ohio
- Cleveland Clinic (Data Collection Only) - Cleveland
Pennsylvania
- Fox Chase Cancer Center (Data Collection Only) - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Washington
- University of Washington (Data Collection Only) - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2026-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05574101
The ClinicalTrials.gov registry entry for NCT05574101 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (67% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT05574101 reports 13 study locations spanning 8 distinct geographic areas - top geographies include New York, New Jersey, Colorado.
Frequently Asked Questions
What is clinical trial NCT05574101 about?
NCT05574101 is a clinical study titled "A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer". The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
What is the current status of trial NCT05574101?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2022-10-06. Estimated completion is 2026-10-06.
What conditions does trial NCT05574101 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Skin Cancer, Cutaneous Squamous Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05574101?
The interventions under investigation include: Cemiplimab (DRUG), Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT05574101?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05574101 being conducted?
This trial has 13 study locations across Colorado, Florida, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.